Stock Track | TG Therapeutics Surges 5% as Positive BRIUMVI Data Set for Presentation at AAN 2025

Stock Track03-07

TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).

The data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.

Highlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197538191?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-08 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197538191","market":"us","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Surges 5% as Positive BRIUMVI Data Set for Presentation at AAN 2025","media":"Stock Track","content":"<p>TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).</p>\n\n<p>The data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.</p>\n\n<p>Highlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Surges 5% as Positive BRIUMVI Data Set for Presentation at AAN 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Surges 5% as Positive BRIUMVI Data Set for Presentation at AAN 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-08 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).</p>\n\n<p>The data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.</p>\n\n<p>Highlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1197538191","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197538191","pubTimestamp":1741374143,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics Inc.  saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI  for the treatment of relapsing forms of multiple sclerosis .The data presentations, which will take place at the American Academy of Neurology  2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"TG Therapeutics股价飙升5%，BRIUMVI数据集将在AAN 2025上展示","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).\nThe data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.\nHighlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197538191"}